FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer

Keyphrases

• Breast Cancer 100%
• Chromatin Silencing 100%
• Breast Cancer Susceptibility Gene 1 (BRCA1) 100%
• Promoter Methylation 100%
• Forkhead Box A1 (FOXA1) 100%
• Enhancer of Zeste Homolog 2 (EZH2) 30%
• Methylation 20%
• Mammary Epithelial Cells 15%
• MRNA Expression 10%
• Chromatin Immunoprecipitation (ChIP) 10%
• Methyltransferase Activity 10%
• Gene Methylation 10%
• H3K27me3 10%
• Patient Survival 5%
• Small Interfering RNA (siRNA) 5%
• Gene Expression 5%
• Co-immunoprecipitation (co-IP) 5%
• Gene Silencing 5%
• Breast Cancer Cells 5%
• Expression Profile 5%
• Knockdown 5%
• Breast Cancer Patients 5%
• MCF-7 5%
• Histone Marks 5%
• Reconstitution 5%
• RNA Analysis 5%
• 5-azacytidine 5%
• Protein Analysis 5%
• Patient Cohort 5%
• Methylation Profile 5%
• Breast Cancer Cell Lines 5%
• Breast Tumor 5%
• Negatively Regulate 5%
• BRCA mutation 5%
• Hypermethylation 5%
• Transcriptional Expression 5%
• DNA Methyltransferase Inhibitor 5%
• Familial Breast Cancer 5%
• GSK126 5%
• DNA Methyltransferase 1 (DNMT1) 5%
• DNA Methyltransferase 3B (DNMT3B) 5%

Biochemistry, Genetics and Molecular Biology

• Promoter Region 100%
• Methylation 100%
• BRCA1 100%
• FOXA1 100%
• EZH2 33%
• Downregulation 16%
• Cancer Cell 11%
• Chromatin Immunoprecipitation 11%
• Methyltransferase 11%
• Messenger RNA 11%
• RNA 5%
• DNA Methylation 5%
• Small Interfering RNA 5%
• Immunoprecipitation 5%
• DNA Methyltransferase 5%
• Protein Characterization 5%
• Histone 5%
• Gene Inactivation 5%